CGON (CG Oncology) ROCE % : -20.78% (As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is CG Oncology ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. CG Oncology's annualized ROCE % for the quarter that ended in Sep. 2024 was -20.78%.

CG Oncology ROCE % Historical Data

The historical data trend for CG Oncology's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CG Oncology ROCE % Chart

CG Oncology Annual Data

Trend

Dec21

Dec22

Dec23

ROCE %

-23.50

-38.10

-34.94

CG Oncology Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial					-28.06	-40.19	-23.83	-18.44	-20.78

CG Oncology ROCE % Calculation

CG Oncology's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-55.449	/	( ( (147.747 - 15.429)	+	(199.301 - 14.254) )	/ 2 )
	=	-55.449	/	( (132.318	+	185.047)	/ 2 )
	=	-55.449	/	158.6825
	=	-34.94 %

CG Oncology's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	-113.18	/	( ( (564.33 - 11.853)	+	(552.471 - 15.63) )	/ 2 )
	=	-113.18	/	( ( 552.477	+	536.841 )	/ 2 )
	=	-113.18	/	544.659
	=	-20.78 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

CG Oncology (NAS:CGON) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

CG Oncology ROCE % Related Terms

Thank you for viewing the detailed overview of CG Oncology's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

CG Oncology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

400 Spectrum Center Drive, Suite 2040, Irvine, CA, USA, 92618

Website

https://www.cgoncology.com

CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.